CSPC Megalith Biopharmaceutical Co.,Ltd.
Registry sponsor category
Industry
- Other names
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Company name
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (36)
- A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
- A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
- A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors
- A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
- A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
- A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
- A Study of SYH2092 Injection in Healthy Participants
- A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
- A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
- A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
- A Study of SYS6051 in Subjects With Advanced Solid Tumors
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
- Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
- Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers